Found 17 grace-kim-lee trials

A listing of grace-kim-lee medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

AK-US-001-0105

99 or below

All genders

The primary objective of this study is to evaluate the effect of EFX compared to placebo on achieving NASH resolution AND fibrosis regression in subjects with fibrosis stage 2 or 3 at Week 52. Subjects meeting the study's eligibility criteria will randomly assigned in a 1:1:1 ratio to 1 of …

Learn More

AK-US-001-0107

99 or below

All genders

This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of EFX in subjects with noninvasively diagnosed NASH/NAFLD. Subjects will be dosed QW with EFX 50 mg or placebo for up to 52 weeks. The safety and tolerability of EFX will be assessed during the study …

Learn More

CVC-HCC

99 or below

All genders

The overarching goal of our Clinical Validation Center for Hepatocellular Carcinoma (CVC-HCC) is to develop a robust infrastructure that will support efficient validation of emerging HCC biomarkers. Our CVC-HCC will also conduct studies to validate novel blood and imaging biomarkers to improve risk stratification and early detection in patients with …

Learn More

TRACER

99 or below

All genders

There is evidence that GALAD, a score that incorporates 3 blood based biomarkers and patient age and sex may be more effective than standard of care screening at detecting HCC early in patients with liver cirrhosis or chronic hepatitis B. Patients undergoing liver cancer screening will be enrolled, then randomized …

Learn More

IDEAL

99 or below

All genders

A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

Learn More

AK-US-001-0106

99 or below

All genders

This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the clinical benefit and safety of EFX in subjects with compensated cirrhosis due to NASH/MASH. The study will enroll in 2 cohorts. Cohort 1 will enroll approximately 750 subjects with biopsy-proven compensated cirrhosis due to NASH/MASH. Cohort 2 will enroll …

Learn More

BDPI-20-004

99 or below

All genders

For a detailed list of objectives, please refer to Section 3, "Objectives" in the latest protocol. For a detailed list of primary outcomes, please refer to the Section 3.1, "Primary Endpoints" in the latest protocol. For detailed list of secondary outcomes, please refer to Section 3.2, " Secondary Endpoints" in …

Learn More

11 - 17 of 17